TY - JOUR
T1 - No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy
AU - Yuan, Peng
AU - Liu, Li
AU - Wu, Chen
AU - Zhong, Rong
AU - Yu, Dianke
AU - Wu, Jing
AU - Xu, Yihua
AU - Nie, Shaofa
AU - Miao, Xiaoping
AU - Sun, Yan
AU - Xu, Binghe
AU - Lin, Dongxin
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Purpose: Genetic polymorphisms in DNA repair genes are thought to represent important determinants of platinum drug efficacy. The current study investigated whether single nucleotide polymorphisms (SNPs) in the X-ray repair cross complementing protein 1 (XRCC1) gene are associated with survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Results: During the median 26.5 months of follow-up, 159 deaths occurred. Regarding XRCC1 Arg194Trp, Arg280His and Arg399Gln genotypes, no significant effects on survival were observed, although the 280Arg/His genotype was associated with a borderline-significant higher median survival time (20.0 months for Arg/His versus 16.0 months for Arg/Arg; p = 0.131). Moreover, no significant association of haplotypes with survival was found. Experimental design: A total of 199 platinum-treated patients with stage III-IV NSCLC were recruited. Overall survival (OS) and progression-free survival (PFS) according to genotypes and haplotypes were analyzed using Kaplan-Meier method and assessed by log-rank test. Hazard ratios (HRs) were calculated using Cox proportional hazards models by adjusting for clinical factors. Conclusions: This study showed no influence of the XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms on survival in advanced NSCLC patients with platinum-based chemotherapy.
AB - Purpose: Genetic polymorphisms in DNA repair genes are thought to represent important determinants of platinum drug efficacy. The current study investigated whether single nucleotide polymorphisms (SNPs) in the X-ray repair cross complementing protein 1 (XRCC1) gene are associated with survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Results: During the median 26.5 months of follow-up, 159 deaths occurred. Regarding XRCC1 Arg194Trp, Arg280His and Arg399Gln genotypes, no significant effects on survival were observed, although the 280Arg/His genotype was associated with a borderline-significant higher median survival time (20.0 months for Arg/His versus 16.0 months for Arg/Arg; p = 0.131). Moreover, no significant association of haplotypes with survival was found. Experimental design: A total of 199 platinum-treated patients with stage III-IV NSCLC were recruited. Overall survival (OS) and progression-free survival (PFS) according to genotypes and haplotypes were analyzed using Kaplan-Meier method and assessed by log-rank test. Hazard ratios (HRs) were calculated using Cox proportional hazards models by adjusting for clinical factors. Conclusions: This study showed no influence of the XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms on survival in advanced NSCLC patients with platinum-based chemotherapy.
KW - Haplotype
KW - Non-small-cell lung cancer
KW - Overall survival
KW - Platinum drug
KW - Polymorphism
KW - Progression-free survival
KW - XRCC1
UR - http://www.scopus.com/inward/record.url?scp=78549243373&partnerID=8YFLogxK
U2 - 10.4161/cbt.10.9.13238
DO - 10.4161/cbt.10.9.13238
M3 - Article
C2 - 20814250
AN - SCOPUS:78549243373
VL - 10
SP - 854
EP - 859
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
SN - 1538-4047
IS - 9
ER -